Metronidazol-Encephalopathie der Ratte

P, von Rogulja; Kovac, W; Schmid, Helena

doi:10.1007/bf00686856

Cited by 57 publications

(27 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[19][20][21][22] A toxicologic study 19 in rats demonstrated well-demarcated usually symmetric lesions in the vestibular nuclei, cochlear nuclei, rostral colliculus, cerebellar nuclei, and olivary nuclei after the administration of high doses of metronidazole, and these lesions were characterized as spongiform changes within neurons. A similar experimental study in dogs demonstrated the degeneration and selective loss of Purkinje cells 20 and mild swelling of axon sheaths in vestibular-cerebellar white matter tracts and leukomalacia near the vestibular nerve radix.…”

Section: Discussionmentioning

confidence: 99%

MR Imaging of Metronidazole-Induced Encephalopathy: Lesion Distribution and Diffusion-Weighted Imaging Findings

Kim¹,

Na²,

Kim³

et al. 2007

American Journal of Neuroradiology

245

201

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

MR Imaging of Metronidazole-Induced Encephalopathy: Lesion Distribution and Diffusion-Weighted Imaging Findings

Kim¹,

Na²,

Kim³

et al. 2007

American Journal of Neuroradiology

245

201

View full text Add to dashboard Cite

show abstract

“…2,3 Hormone-replacement therapy was significantly associated with worsening urinary incontinence. 4 Side effects of hormone-replacement therapy included breast tenderness and uterine bleeding, and only 70 percent of the women remained adherent to therapy by the end of year 3. 2 Manson and Martin did not include stroke in their evaluation of benefits and risks.…”

Section: Postmenopausal Hormone-replacement Therapymentioning

confidence: 99%

“…1,2 In vitro and in vivo studies provide no evidence that such supplementation protects against breast cancer or is even safe. 3,4 Concurrent use of high doses of phytoestrogen supplements and tamoxifen in women with breast cancer should be discouraged until further information is available, because of the potential for isoflavones to antagonize the desired antiestrogenic effects of tamoxifen. The authors reply:…”

Section: To the Editormentioning

confidence: 99%

“…Indeed, such therapy is associated with corpus-predominant gastritis in H. pylori-infected patients. Although it is uncertain whether the use of protonpump inhibitors leads to atrophic gastritis, 3,4 it is clearly associated with epithelial-cell hyperproliferation in the gastric body, 5 which is a precancerous change. Assuming that all 253 patients with H. pylori infection who received eradication therapy had gastric or duodenal ulcers, the remaining 319 patients with ulcers had ongoing infection.…”

Section: Berea Health Centermentioning

confidence: 99%

“…4 Side effects of hormone-replacement therapy included breast tenderness and uterine bleeding, and only 70 percent of the women remained adherent to therapy by the end of year 3.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Reversible Metronidazole-Induced Lesions of the Cerebellar Dentate Nuclei

Woodruff¹,

Wijdicks²,

Marshall³

2002

N Engl J Med

View full text Add to dashboard Cite

Manson and Martin review the clinical controversies surrounding hormone-replacement therapy. 1 The findings of the Heart and Estrogen/Progestin Replacement Study (HERS) suggest reasons to be cautious about the use of hormonereplacement therapy in women who are 65 years of age or older. Of 2763 women (mean age, 67 years) with established coronary heart disease, women who were randomly assigned to receive hormone-replacement therapy had an excess risk of one additional blood clot per 64 women and of one additional gallbladder operation per 69 women during a fouryear period.2,3 Hormone-replacement therapy was significantly associated with worsening urinary incontinence. 4 Side effects of hormone-replacement therapy included breast tenderness and uterine bleeding, and only 70 percent of the women remained adherent to therapy by the end of year 3. 2Manson and Martin did not include stroke in their evaluation of benefits and risks. Among 652 women (mean age, 71 years) who had had a transient ischemic attack or nondisabling stroke, women who were randomly assigned to receive oral estradiol did not have lower rates of death or stroke. 5 The risk of fatal stroke was significantly increased (relative risk, 3.86; 95 percent confidence interval, 1.09 to 13.63) with the use of estrogen therapy. 5Before older women begin receiving hormone-replacement therapy, clinicians should inform them of the increased risk of blood clots, gallbladder disease, urinary incontinence, and fatal stroke. Clinicians should correct the misperception that hormone-replacement therapy is cardioprotective, since both the Women's Health Initiative 6 and HERS reported an increased risk of cardiovascular events in the first one to two years of use. Clinicians should alert women that, in 1999, the Food and Drug Administration removed the treatment of osteoporosis as an indication for estrogen therapy because of the lack of evidence from randomized trials of the effect of estrogen on the risk of fracture.

show abstract